

PREVENTIVE CARE

HIV PRE-EXPOSURE PROPHYLAXIS (PrEP)


STATEWIDE DRUG THERAPY MANAGEMENT PROTOCOL for the OREGON PHARMACIST

AUTHORITY and PURPOSE: Per [ORS 689.645](#), a pharmacist may provide patient care services pursuant to a statewide drug therapy management protocol.

- Following all elements outlined in [OAR 855-020-0110](#), a pharmacist licensed and located in Oregon may prescribe pre-exposure prophylaxis (PrEP) drug regimen.
- **STANDARDIZED PATIENT ASSESSMENT PROCESS ELEMENTS:**
 - Utilize the standardized PrEP Patient Intake Form (pg. 2-3)
 - Utilize the standardized PrEP Assessment and Treatment Care Pathway (pg.4-8)
 - Utilize the standardized PrEP Provider Fax (pg.10)

PHARMACIST TRAINING/EDUCATION:

- Completion of a comprehensive training program related to the prescribing and dispensing of HIV prevention medications, to include related trauma-informed care



Pre-Exposure Prophylaxis (PrEP) Self-Screening Patient Intake Form

(CONFIDENTIAL-Protected Health Information)

Date ____/____/____ Date of Birth ____/____/____ Age ____
 Legal Name _____ Name _____
 Sex Assigned at Birth (circle) M / F Gender Identification (circle) M / F / Other ____
 Pronouns (circle) She/Her/Hers, He/Him/His, They/Them/Their, Ze/Hir/Hirs, Other _____
 Street Address _____
 Phone () _____ Email Address _____
 Healthcare Provider Name _____ Phone () _____ Fax () _____
 Do you have health insurance? Yes / No Insurance Provider Name _____
 Any allergies to medications? Yes / No If yes, please list _____

Background Information: These questions are highly confidential and help the pharmacist to determine if PrEP is right for you and what Human Immunodeficiency Virus (HIV) and Sexually Transmitted Infection (STI) testing is recommended.

Do you answer yes to any of the following? yes no

1. Do you want to start or continue PrEP?
2. Do you sexually partner with men, women, transgender, or non-binary people?
3. Please estimate how often you use condoms for sex. Please estimate the date of the last time you had sex without a condom. _____% of the time __/__/__ last sex without a condom
4. Do you have oral sex? <ul style="list-style-type: none"> • Giving- you perform oral sex on someone else • Receiving- someone performs oral sex on you
5. Do you have vaginal sex? <ul style="list-style-type: none"> • Receptive- you have a vagina and you use it for vaginal sex • Insertive- you have a penis and you use it for vaginal sex
6. Do you have anal sex? <ul style="list-style-type: none"> • Receptive- someone uses their penis to perform anal sex on you • Insertive- you use your penis to perform anal sex on someone else
7. Do you inject drugs?
8. Are you in a relationship with an HIV-positive partner?
9. Do you exchange sex for money or goods? (includes paying for sex)
10. Do you use poppers (inhaled nitrates) and/or methamphetamine for sex?

Medical History: These questions are highly confidential and help the pharmacist to determine if PrEP is right for you.

1. Have you ever tested positive for Human Immunodeficiency Virus (HIV)?	<input type="checkbox"/> yes <input type="checkbox"/> no
2. Have you had any of the following in the last 4 weeks: fever, feeling very tired, muscle or joint aches or pain, rash, sore throat, headache, night sweats, swollen lymph nodes, diarrhea, general flu-like symptoms?	<input type="checkbox"/> yes <input type="checkbox"/> no
3. When was your last possible HIV exposure?	<input type="checkbox"/> < 72 hrs ago <input type="checkbox"/> 72 hrs – 4 weeks ago <input type="checkbox"/> > 4 weeks ago
4. Have you ever had Hepatitis B Infection?	<input type="checkbox"/> yes <input type="checkbox"/> no
5. Have you ever received an immunization for Hepatitis B? If yes, when: <ul style="list-style-type: none"> • If no, would you like a Hepatitis B immunization today? <input type="checkbox"/> yes <input type="checkbox"/> no 	<input type="checkbox"/> yes <input type="checkbox"/> no Date of vaccine __/__/__

Pre-Exposure Prophylaxis (PrEP) Self-Screening Patient Intake Form

(CONFIDENTIAL-Protected Health Information)

6. Have you ever been told you have a bone disease (e.g. osteoporosis, low bone mineral density, etc.)?	<input type="checkbox"/> yes <input type="checkbox"/> no
7. Do you see a healthcare provider for problems with your kidneys?	<input type="checkbox"/> yes <input type="checkbox"/> no
8. Do you take non-steroid anti-inflammatory drugs (NSAIDs)? • Includes: Advil/Motrin (ibuprofen), aspirin, Aleve (naproxen)	<input type="checkbox"/> yes <input type="checkbox"/> no
9. Are you currently or planning to become pregnant or breastfeeding?	<input type="checkbox"/> yes <input type="checkbox"/> no
10. Do you have any other medical problems the pharmacist should know? If yes, list them here: _____	<input type="checkbox"/> yes <input type="checkbox"/> no

Testing and Treatment:

<p>1. I understand that I must get an HIV test every 90 days to get my PrEP prescription filled. The pharmacist must document a negative HIV test to fill my PrEP prescription.</p> <ul style="list-style-type: none">• I may be able to have tests performed at the pharmacy.• I can bring in my HIV test results, showing negative HIV and/or STI testing, within the last 7 days.<ul style="list-style-type: none">○ I brought my labs in today <input type="checkbox"/> Yes <input type="checkbox"/> No <p>I understand that if I have condomless sex within 2 weeks before and between the time I get my HIV test and when I get my PrEP that the test results may not be accurate. This could lead to PrEP drug resistance if I become HIV positive and I will need a repeat HIV test within one month.</p>
<p>2. I understand that I must complete STI screening at least every 6 months while on PrEP. Undiagnosed STIs will increase the risk of getting HIV.</p> <p>I understand if I have condomless sex between the time I get my STI testing and when I get my PrEP that the results may not be accurate.</p>
<p>3. I understand that the effectiveness of PrEP is dependent on my taking all my doses. Missing doses increases the risk of getting HIV.</p>

Please write down the names of any prescription or over the counter medications or supplements you take. Please include herbal and nutritional products as well. This helps the pharmacist make sure there are no harmful interactions with your PrEP.

Please list any questions you have for the pharmacy staff:

--

Patient Signature: _____ **Date:** _____

Pre-Exposure Prophylaxis (PrEP) Assessment and Treatment Care Pathway

(CONFIDENTIAL- Protected Health Information)

Name _____ Date of Birth _____ Age _____ Today's Date _____

Background Information/ HIV and STI risk factors:

Document that a risk factor is present (circle below) and refer to the notes and considerations below to evaluate the risk factor(s). If a person has one or more risk factor, PrEP is recommended. The HIV Warmline offers consultations for providers from HIV specialists and is available every day at: (855) 448-7737. For information about PrEP, please visit the [CDC website](https://www.cdc.gov/hiv).

Risk Factor:	Notes and considerations
1. Patient requests PrEP	<ul style="list-style-type: none"> • Patient may not be comfortable sharing detailed sexual history per CDC PrEP guidelines, if a patient requests PrEP, the recommendation is to prescribe it regardless of identified HIV exposure risk.
2. Sexual partners	<ul style="list-style-type: none"> • MSM activity is highest risk for HIV. • Men who have insertive vaginal sex may not be at high risk of HIV unless other risk factors are present.
3. Estimated condom use _____% of the time __/__/__ last sex without a condom	<ul style="list-style-type: none"> • Condomless sex greatly increases risk of HIV and STIs. • For patients with condomless sex within the last 72 hours, consider Post-Exposure Prophylaxis (PEP). • Condomless sex within last 14 days, repeat HIV test in one month.
4. Oral sex	<ul style="list-style-type: none"> • Oral sex is not considered high risk for HIV unless there is blood or ulcerations in the mouth or genitals. • STIs such as gonorrhea and chlamydia can inhabit the mouth and should be screened for in persons who have oral sex.
5. Vaginal sex	<ul style="list-style-type: none"> • Receptive vaginal sex can be high risk for HIV. • Insertive vaginal sex is not considered high risk for HIV unless other risk factors are present.
6. Anal sex	<ul style="list-style-type: none"> • Receptive anal sex has the most risk of HIV of any sex act. • Insertive anal sex has high risk for HIV. • STIs such as gonorrhea and chlamydia can inhabit the rectum and should be screened in persons who have anal sex.
7. Injection drug use	<ul style="list-style-type: none"> • Injection drug use is high risk for HIV. Consider referral for syringe exchange or sale of clean syringes.
8. HIV-positive partner	<ul style="list-style-type: none"> • People living with HIV who have undetectable viral loads will not transmit HIV. • For partners of people living with HIV, consider partner's HIV viral load when recommending PrEP.
9. Exchanging sex for money or goods	<ul style="list-style-type: none"> • People who buy or sell sex are at high risk for HIV.
10. Popper or methamphetamine use	<ul style="list-style-type: none"> • Popper (inhaled nitrates) and methamphetamine use is associated with an increased risk of HIV. • Recommend adequate lubrication in persons who use poppers for sex.

1. Is one or More Risk Factor Present? **yes** **no**

- If yes, HIV PrEP is recommended. Proceed to next section: Testing.
- If no, HIV PrEP is not recommended. Refer to a healthcare provider.

Pre-Exposure Prophylaxis (PrEP) Assessment and Treatment Care Pathway

(CONFIDENTIAL- Protected Health Information)

Testing:

The pharmacist must verify appropriate labs are complete. *Italics* below indicate need for referral.

Needs referral

Test Name	Date of Test	Result	Needs referral
• HIV Ag/Ab (4th gen) test:	___/___/___	<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> <i>indeterminate</i> <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
• HIV RNA test:	___/___/___	<input type="checkbox"/> <i>detected</i> <input type="checkbox"/> <i>indeterminate</i> <input type="checkbox"/> not detected	<input type="checkbox"/> Yes
<i>Reactive and indeterminate tests are an automatic referral to county health or the patient's healthcare provider for confirmatory testing. NOTE: HIV Ag/Ab test must be performed within the 7 days prior to prescribing and dispensing. Order lab at initial intake and every 90 days thereafter.</i>			
• Syphilis/Treponemal antibody:	___/___/___	<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> <i>indeterminate</i> <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
<i>Reactive treponemal antibody testing will result in an automatic referral to county health or the patient's primary care provider for follow-up and confirmatory testing. Order lab at initial intake and every 90-180 days depending on risk.</i>			
• Hepatitis B surface antigen:	___/___/___	<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
<i>Positive surface antigen indicates either acute or chronic Hepatitis B and PrEP should be referred to county health or a specialist physician. Confirmation of being fully vaccinated for hepatitis B via ALERT or medical record may meet criteria for negative Hepatitis B surface antigen. If records of vaccination are not available, order lab at initial intake only.</i>			
• Hepatitis C antibody (recommended, optional):	___/___/___	<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
<i>Recommended for men who have sex with men, transgender women who have sex with men, and persons with illicit or injection drug use. At least annual screenings and every 3 to 6 months for those with injection drug use. Positive antibody indicates exposure to Hepatitis C virus. The pharmacist will refer this person for confirmatory testing and treatment. It is permissible to proceed with PrEP prescribing in this scenario.</i>			
• Gonorrhea/Chlamydia:	___/___/___		<input type="checkbox"/> Yes
Urinalysis result:	Pharyngeal test result:	Rectal test result:	
<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> <i>indeterminate</i>	<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> <i>indeterminate</i>	<input type="checkbox"/> <i>reactive</i> <input type="checkbox"/> <i>indeterminate</i>	
<input type="checkbox"/> non-reactive	<input type="checkbox"/> non-reactive	<input type="checkbox"/> non-reactive	
<i>Patients can determine which sites need to be screened. All reactive or indeterminate chlamydia or gonorrhea results must be reported to the County Health Department and Oregon Health Authority and will result in an automatic referral to county health or the patient's healthcare provider for evaluation and treatment. Order lab at initial intake and every 90-180 days depending on risk.</i>			
• Renal function (CrCl):	___/___/___	_____ mL/min <input type="checkbox"/> CrCl > 60 mL/min	<input type="checkbox"/> Yes
SCr _____mg/dL		<input type="checkbox"/> CrCl 30-60 mL/min	
		<input type="checkbox"/> CrCl < 30 mL/min	
<i>CrCl > 60mL/min: Kidney function adequate for PrEP; CrCl 30-60mL/min: Only Descovy indicated; CrCl <30 mL/min: referral for evaluation/follow-up. NOTE: Concurrent NSAID use would favor Descovy. Order lab at initial intake and annually thereafter; if over 50 years old and on emtricitabine/tenofovir DF (Truvada) PrEP order every 6 months.</i>			
• HCG:	___/___/___	<input type="checkbox"/> positive <input type="checkbox"/> <i>indeterminate</i> <input type="checkbox"/> negative	<input type="checkbox"/> Yes
<i>Applies to anyone who may become pregnant; frequency can be from every 3 to 12 months per patient preference and pharmacist clinical judgment. Refer to healthcare provider if positive.</i>			
• Signs/symptoms of acute retroviral syndrome (<input type="checkbox"/> Present <input type="checkbox"/> Not Present) AND potential HIV exposure (<input type="checkbox"/> Yes <input type="checkbox"/> No) in the last 4 weeks AND not on PrEP (<input type="checkbox"/> Yes <input type="checkbox"/> No)			<input type="checkbox"/> Yes
<i>If signs/symptoms present and answered yes to potential HIV exposure and not on PrEP, do NOT prescribe PrEP; Urgently refer to PCP, HIV specialist, or PrEP specialist or community organization¹ to link to care and evaluation</i>			
• Signs/symptoms of acute retroviral syndrome and potential exposure <i>while on PrEP.</i>			<input type="checkbox"/> Yes
<input type="checkbox"/> Present <input type="checkbox"/> Not Present			
<i>If present, eligible for PrEP for up to a 30-day supply. Order HIV RNA and repeat HIV Ag/Ab within 7 days of the next prescription or refer to PrEP provider or Infectious Disease provider for further evaluation.</i>			
• Exposure risk less than 72 hours ago?		<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes

Pre-Exposure Prophylaxis (PrEP) Assessment and Treatment Care Pathway

(CONFIDENTIAL- Protected Health Information)

2. Is HIV Ab/Ag 4th gen test resulted? yes/non-reactive yes/reactive or indeterminate no

- If yes and non-reactive: Proceed to question #3
- If yes and reactive or indeterminate: Do NOT prescribe PrEP. Patient should be referred to healthcare provider. NOTE: Sample language below.
- If no, do NOT prescribe PrEP, obtain HIV Ab/Ag 4th gen test. Repeat question #2 once results are available.

3a. If initial visit: Are syphilis, gonorrhea, chlamydia, Hepatitis B serologies (if no documentation of complete vaccination), and serum creatinine resulted? yes no

- If yes, RPH may prescribe PrEP for up to a 90 day supply. Proceed to next section: Medical History.
- If no, RPH may prescribe PrEP for up to a 30 day supply and the patient needs to complete all required labs and bring them in within 30 days before next refill. Proceed to next section: Medical History.

→ See next page for follow-up visit lab requirements and sample language for reactive (indeterminate) HIV and STI tests.

3b. If follow-up visit: Are required follow-up labs resulted? yes no

- Every 90 days- HIV
- Every 90-180 days- Syphilis/Treponemal antibody and Gonorrhea/Chlamydia; Renal function if > 50 yrs old and on emtricitabine/tenofovir DF (Truvada)
- Annually - Renal function
- If yes, RPH may prescribe PrEP for up to a 90 day supply. Proceed to next section: Medical History.
- If no, RPH may prescribe PrEP for up to a 30 day supply; patient needs to complete all required labs and bring them in within 30 days. Proceed to next section: Medical History.

Sample language for reactive or indeterminate tests:

Your HIV test has tested reactive (or indeterminate). This is not a diagnosis of HIV or AIDS. We will need to confirm that this is the true result or to confirm a result with a more specific test before a diagnosis can be made. We are going to refer you to your health care provider (or your county health department) so that they may perform the confirmatory test and clarify the result. Until you have had your confirmatory test, we are going to recommend you abstain from any condomless sexual activity. We will delay starting (or refilling) your PrEP until we have confirmation, you're HIV negative.

Your STI test has tested reactive (or indeterminate). This is not a diagnosis of (chlamydia, gonorrhea, or syphilis). We will need to confirm that this is the true result or to confirm a result with a more specific test before a diagnosis can be made. We are going to refer you to your health care provider (or your county health department) so that they may perform the confirmatory test and clarify the result. Until you have had your confirmatory test, we are going to recommend you abstain from any condomless sexual activity including giving or receiving oral sex.

County Health Department Directory:

<https://www.oregon.gov/oha/ph/providerpartnerresources/localhealthdepartmentresources/pages/lhd.aspx>

Oregon AIDS Education and Training Center List of PrEP and PEP Resources, PrEP Navigation Services, STI and HIV testing and treatment sites and community organizations: <https://www.oraetc.org/prep> <https://www.oraetc.org/pep-resource-list>

Lab Reporting: The [disease reporting poster](#) for clinicians summarizes rules and lists the diagnoses for which lab-confirmed and clinically suspect cases must be reported within one working day to the Local Public Health Authority (LPHA). People reporting cases are encouraged to use the [online morbidity report system](#), but a [fillable PDF](#) is also available to fax to [LPHA](#).

Medical History: The following are referral conditions and considerations for pharmacist prescribing of PrEP. If a patient has one or more contraindications, the pharmacist must refer the patient to a specialist for consultation or management of PrEP.

Pre-Exposure Prophylaxis (PrEP) Assessment and Treatment Care Pathway

(CONFIDENTIAL- Protected Health Information)

Medical history factor	Notes and considerations
REFERRAL CONDITIONS	
1. Positive HIV test <i>Needs Referral:</i> <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• A positive or indeterminate HIV test either indicates HIV infection, a false positive, or a result requiring specialist interpretation.• Confirmatory testing is beyond the testing capacity of the community pharmacist and the patient should be referred for PrEP management.
2. Symptoms of acute retroviral syndrome in last 4 weeks <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• Could have acute HIV with negative screening HIV Ag/Ab result.• Order HIV RNA and refer to PrEP provider or Infectious Disease provider for further evaluation.
3. Exposure risk was: < 72 hrs ago <input type="checkbox"/> yes <input type="checkbox"/> no >72 hours to 4 weeks ago <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• If exposure <72 hours ago, screen for eligibility for PEP (see OBOP Protocol for PEP Prescribing) OR refer to urgent care or ED for further evaluation and possible PEP initiation.• If exposure 72 hours to 4 weeks ago, eligible for up to a 30-day supply of PrEP. Order HIV RNA test now and repeat HIV Ag/Ab within 7 days of next assessment; review symptoms of acute retroviral syndrome and need for urgent evaluation should symptoms develop.
4. Presence of Hepatitis B infection <i>Needs Referral:</i> <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• Truvada and Descovy are treatments for Hepatitis B. In patients with Hepatitis B who stop PrEP, this may cause a HepB disease flare.• People with HepB infection must have their PrEP managed by a gastroenterologist or infectious disease specialist.
5. Presence of Hepatitis C exposure <i>Needs Referral:</i> <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• People with HepC exposure must be referred to primary care or other appropriate community health outreach organization (see Oregon AIDS Education and Training Center website for list above). Pharmacist may proceed with prescribing PrEP.
6. Impaired kidney function (<30mL/min) <i>Needs Referral:</i> <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• Truvada is approved for patients with a CrCl >60mL/min.• Consider Descovy in cis-gender men and male to female transgender women who have risk factors for kidney disease with a CrCl >30mL/min, but less than 60mL/min.• Pharmacist prescribing of PrEP is contraindicated for patients who are under the care of a specialist for chronic kidney disease.
7. Other medications <i>Needs Referral:</i> <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• Evaluate for comorbid medications that can be nephrotoxic or decrease bone mineral density.• For cis-gender men and male to female transgender women who are on medications that could be nephrotoxic or could lower bone mineral density, consider Descovy over Truvada.
CONSIDERATIONS	
8. NSAID use Precaution- Counseled on limiting use: <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• Tenofovir use in conjunction with NSAIDs may increase the risk of kidney damage.• Concurrent use is not contraindicated, but patient should be counseled on limiting NSAID use.
9. Hepatitis B vaccinated If not, would the patient like to be vaccinated? <input type="checkbox"/> yes <input type="checkbox"/> no	<ul style="list-style-type: none">• Vaccination for Hepatitis B is preferred, but lack of vaccination is not a contraindication for PrEP.• Counsel on risk factors for Hepatitis B and recommend vaccination.• If patient would like to be vaccinated, proceed according to OAR 855-019-0280.
10. Pregnant or breastfeeding	<ul style="list-style-type: none">• Pregnancy and breastfeeding are not contraindications for PrEP.• Women at risk of HIV who are also pregnant are at higher risk of intimate partner violence.• Truvada is preferred due to better data in these populations.

4. Are One or More Referral Condition(s) Present? yes no

- *If yes, HIV PrEP is recommended but pharmacists are not authorized to prescribe in accordance with this RPH protocol. Refer the patient for further evaluation and management of PrEP by the patient's healthcare provider or appropriate specialist.*
- *If no, HIV PrEP is recommended and pharmacists are authorized to prescribe and dispense PrEP in accordance with this RPH protocol. Proceed to next sections: Regimen Selection and Prescription.*

Pre-Exposure Prophylaxis (PrEP) Assessment and Treatment Care Pathway

(CONFIDENTIAL- Protected Health Information)

Regimen Selection:

Considerations*	Preferred regimen
Cis-gender male or male to female transgender woman. <ul style="list-style-type: none"> • Both Truvada and Descovy are FDA approved in these populations. May prescribe based on patient preference. 	May choose Truvada or Descovy
Cis-gender female or female to male transgender man. <ul style="list-style-type: none"> • Only Truvada is FDA approved in these populations. • If patient has low bone mineral density or renal function that would preclude Truvada use, but has risk factors for HIV, refer the patient to a specialist for PrEP management. 	Truvada
NSAID use <ul style="list-style-type: none"> • If patient is male or a male to female transgender woman, consider Descovy 	Descovy
Patient has some kidney impairment (CrCl <60mL/min) but is not under care of nephrologist. <ul style="list-style-type: none"> • If patient is male or male to female transgender woman, consider Descovy 	Descovy
Patient has decreased bone mineral density or on medications that affect bone mineral density. <ul style="list-style-type: none"> • If patient is male or male to female transgender woman, consider Descovy. 	Descovy
Patient is pregnant or breastfeeding <ul style="list-style-type: none"> • Descovy has not been studied in these populations. Truvada is approved in these populations. 	Truvada

*generic versions are acceptable in all cases if available.

PrEP Prescription

Optional-May be used by pharmacy if desired

Patient Name:	Date of birth:
Address:	
City/State/Zip Code:	Phone number:

Verified DOB with valid photo ID

Note: RPh may not prescribe and must refer patient if HIV test reactive or indeterminate

Rx

Truvada (emtricitabine/tenofovir disoproxil fumarate) 200/300mg tablets

- Take one tablet by mouth daily for 90 days, #90, 0 refills

-or-

Descovy (emtricitabine/tenofovir alafenamide) 200/25mg tablets

- Take one tablet by mouth daily for 90 days, #90, 0 refills

Written Date: _____

Expiration Date: (This prescription expires 90 days from the written date) _____

Prescriber Name: _____ Prescriber Signature: _____

Pharmacy Address: _____ Pharmacy Phone: _____

-or-

Patient Referred

Hepatitis B Vaccination administered:

Lot: _____ Expiration Date: _____ Dose: _____ of 2 or 3 (circle one)

Notes: _____

Manufacturer Copay Card Information:

RXBIN:	RXPCN:	GROUP:
ISSUER:	ID:	

Provider Notification

Pre-Exposure Prophylaxis (PrEP) for Human Immunodeficiency Virus (HIV)

Pharmacy Name: _____ Pharmacist Name: _____

Pharmacy Address: _____

Pharmacy Phone: _____ Pharmacy Fax: _____

Dear Provider _____ (name) (____) ____ - _____ (FAX)

Your patient _____ (name) ____/____/____ (DOB) has been prescribed HIV Pre-Exposure Prophylaxis (PrEP) by _____, RPH. This regimen was filled on ____/____/____ (Date) and follow-up HIV testing is recommended in approximately 90 days ____/____/____ (Date)

This regimen consists of the following (check one):

- | | |
|--|---|
| <input type="checkbox"/> Truvada (emtricitabine/tenofovir disoproxil fumarate) 200/300mg tablets
<ul style="list-style-type: none"> • Take one tablet by mouth daily | <input type="checkbox"/> Descovy (emtricitabine/tenofovir alafenamide) 200/25mg tablets
<ul style="list-style-type: none"> • Take one tablet by mouth daily |
|--|---|

Your patient has been tested for and/or indicated the following:

Test Name	Date of Test	Result	Needs referral
• HIV ag/ab (4th gen):	____/____/____	<input type="checkbox"/> reactive <input type="checkbox"/> indeterminate <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
• HIV RNA	____/____/____	<input type="checkbox"/> detected <input type="checkbox"/> indeterminate <input type="checkbox"/> not detected	<input type="checkbox"/> Yes
• Syphilis/Treponemal antibody:	____/____/____	<input type="checkbox"/> reactive <input type="checkbox"/> indeterminate <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
• Hepatitis B surface antigen:	____/____/____	<input type="checkbox"/> reactive <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
• Hepatitis C antibody:	____/____/____	<input type="checkbox"/> reactive <input type="checkbox"/> non-reactive	<input type="checkbox"/> Yes
• Gonorrhea/Chlamydia:	____/____/____		<input type="checkbox"/> Yes
Urinalysis result:	Pharyngeal test result:	Rectal test result:	
<input type="checkbox"/> reactive <input type="checkbox"/> indeterminate	<input type="checkbox"/> reactive <input type="checkbox"/> indeterminate	<input type="checkbox"/> reactive <input type="checkbox"/> indeterminate	
<input type="checkbox"/> non-reactive	<input type="checkbox"/> non-reactive	<input type="checkbox"/> non-reactive	
• Renal function (CrCl):	____/____/____ mL/min		<input type="checkbox"/> Yes
<input type="checkbox"/> CrCl >60mL/min	<input type="checkbox"/> CrCl 30mL/min - 60mL/min	<input type="checkbox"/> CrCl <30mL/min	
• HCG:	____/____/____	<input type="checkbox"/> positive <input type="checkbox"/> indeterminate <input type="checkbox"/> negative	<input type="checkbox"/> Yes
• Signs/symptoms of acute retroviral syndrome (<input type="checkbox"/> Present <input type="checkbox"/> Not Present) AND potential HIV exposure (<input type="checkbox"/> Yes <input type="checkbox"/> No) in the last 4 weeks and not on PrEP (<input type="checkbox"/> Yes <input type="checkbox"/> No).			<input type="checkbox"/> Yes
• Exposure risk less than 72 hours ago? <input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> Yes

We recommend evaluating the patient, confirming the results, and treating as necessary. *Listed below are some key points to know about PrEP.*

Provider pearls for HIV PrEP:

- PrEP is prescribed for up to a 90 day supply for each prescription to align with appropriate lab monitoring guidelines.
- Truvada is not recommended for CrCl less than 60 mL/min. Please contact the pharmacy if this applies to your patient and/or there is a decline in renal function. Descovy may be a better option.
- Truvada and Descovy are both safe in pregnancy. If your patient is pregnant or becomes pregnant, they may continue PrEP.
- NSAIDs should be avoided while patients are taking HIV PrEP to avoid drug-drug interactions with Truvada.
- Truvada is a first line option for Hepatitis B treatment. This is not a contraindication to PrEP use, but we recommended you refer Hepatitis B positive patients to an infectious disease or gastroenterology specialist.
- A positive STI test is not a contraindication for PrEP.

Pharmacist monitoring of HIV PrEP and transition of care:

- The pharmacist prescribing and dispensing PrEP conducts and/or reviews results of HIV testing, STI testing, and other baseline and treatment monitoring lab results as part of their patient assessment.
- Patients who test reactive or indeterminate for HIV, gonorrhea/chlamydia, syphilis, or Hepatitis B will be referred to your office for evaluation, diagnosis, and treatment.
- Your office may take over management of this patient’s HIV PrEP from the pharmacy at any time.

If you have additional questions, please contact the prescribing pharmacy, or call the HIV Warmline. The HIV Warmline offers consultations for providers from HIV specialists and is available every day at: (855) 448-7737. For information about PrEP, please visit the [CDC website](https://www.cdc.gov/hiv).